SPRYCanada says yes
ARS Pharmaceuticals got the nod from Health Canada for neffy 2 mg, its needle-free emergency treatment for allergic reactions. That means the company can now sell the product in Canada for adults and children weighing at least 30 kg — a nice little expansion for a drug that’s basically trying to make “epinephrine auto-injector” feel a bit more 2026.
Why this matters
For investors, this is less about one approval and more about the rollout story. neffy has been working its way into more geographies, and every new country is another chance to turn a specialty product into a real revenue engine instead of just a promising science project.
The ALK-Abelló angle
The company also pointed to its partnership with ALK-Abelló, which will market neffy across Europe, Canada, the U.K., and select markets outside the U.S. In other words, ARS isn’t trying to build the whole international distribution machine from scratch — it’s borrowing someone else’s runway.
Big picture
Approvals like this don’t usually send a stock into orbit by themselves, but they do matter. More territory, more access, more shots on goal. For a company like ARS, that’s the difference between a niche launch and a product that actually gets to stretch its legs.